In the fourth instalment of our Medical Monitoring Masterclass to celebrate Clinical Trials Day 2026, we’re looking at why biosimilar trials require specialist monitoring along with immunogenicity – one of the most important considerations in biosimilar development.

Biosimilars: Opportunities and Challenges

The biosimilar market represents one of the most significant growth opportunities in the pharmaceutical industry. As patents on major biologics expire, the potential to build commercially successful programmes, which bring high-quality, lower-cost alternatives to patients, is substantial.

But biosimilar development is not simple. The complexity of manufacturing and standardising biological molecules, the requirement to demonstrate biosimilarity to an innovator that may itself have varied over time, and the evolving regulatory landscape all create challenges that demand specialist expertise at every stage of development.

Why Biosimilar Trials Require Specialist Medical Monitoring

Biosimilar clinical programmes are designed to demonstrate that a candidate molecule is highly similar to its reference biologic in terms of safety, efficacy, and immunogenicity – not to establish the clinical profile of a new medicine from scratch. This creates a specific and important medical monitoring challenge.

The medical monitor responsible for a biosimilar programme must understand not just the general principles of clinical trial oversight, but the specific safety profile of the reference biologic, the immunogenic risks associated with biological molecules, and the regulatory standards for comparative safety data. Any divergence from the expected safety profile of the reference product must be interpreted in this specific context – and that interpretation requires deep expertise.

Immunogenicity: A Critical Focus

One of the most important safety considerations in biosimilar development is immunogenicity: the potential for a biological molecule to trigger an immune response. Such responses can reduce the efficacy of the product (e.g. due to neutralising anti-drug antibodies) and could lead to serious adverse events. The medical monitor must ensure that immunogenicity data are systematically collected, reviewed, and interpreted throughout the clinical programme, and that any signals are escalated and managed appropriately.

This is an area where experience matters enormously. At Pharmora, our team has hands-on experience monitoring biological therapies across a range of therapeutic areas, and we understand the clinical significance of immunogenicity signals in the context of both patient safety and regulatory review.

Regulatory Compliance in a Shifting Landscape

The implementation of ICH E6(R3) principles in the UK from April 2026, with their emphasis on quality by design and risk-proportionate oversight, applies as fully to biosimilar trials as to any other clinical programme. For biosimilar developers, this means designing monitoring plans that are specifically tailored to the known risks of the reference biologic and the specific comparability endpoints of the trial.

Pharmora’s medical monitoring teams work closely with sponsors to develop risk-adapted monitoring strategies that are proportionate, efficient, and fully compliant with current regulatory expectations.

Supporting the Comparability Story

Ultimately, the success of a biosimilar programme depends on the strength of the comparability story presented to regulators. High-quality, well-monitored clinical safety data are a critical component of that story. Gaps in monitoring, inconsistencies in adverse event management, or weaknesses in data integrity can undermine the argument for comparability – even when the underlying science is sound.

At Pharmora, we understand the regulatory narrative that biosimilar programmes need to construct, and we provide medical monitoring that supports and strengthens that narrative at every stage.

In case you missed a previous instalment, or are looking to read the rest of this exciting masterclass, click the links below to navigate through the series:
1 – What is it and why does it matter?
2 – Medical Monitoring for Biotechs
3 – Medical Monitoring and the Investor Perspective
5 –  Medical Monitoring in Generics Development

To find out how Pharmora can support your programme, contact us at info@pharmora.com or visit www.pharmora.com.